| abstract |
nanometric pharmaceutical composition for the release of interference rna molecules and their use. The present invention relates to a nanoscale composition in the form of liposomes or nanoemulsions containing interfering RNA (sirna) filaments capable of silencing the gene responsible for expression of overexposed adhesion proteins in tumors, such as the ecto-5? -nucleotidase / cd73 (cd73) overexpressed in glioblastoma multiforme and other tumor types. The union of liposomes or nanoemulsions with sirna promotes a site-directed release complex that can be incorporated into various types of formulation, such as intratumoral, intravenous injection or nasal administration. |